News | 24 August 2023
Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ
The company has entered into a three-year Deferred Prosecution Agreement
The company has entered into a three-year Deferred Prosecution Agreement
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Rs. 64000 crores are being invested across the 750 districts of India, to create a more resilient healthcare system in the country
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Eris Lifesciences enters into term loan agreement with Citi Bank
Jupiter has filed its draft herring prospectus (DRHP) with the market regulator in May this year, to float its IPO
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The offer for sale comprises of up to Rs. 383 crore by Vishal Rakesh Agrawal, up to Rs. 383 crore by Rahul Rakesh Agrawal, and up to Rs. 134 crore by Geetganga Investment
The antibacterial market in Oman is worth US $7.5 million, and Elores is looking to capture 0.5 per cent of this segment by year 2025
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon
Jeet will be a trusted partner in cardiovascular care
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
The survey findings for Delhi-NCR revealed that speech sound disorders exhibit higher prevalence rates in the 6-12 years age group
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated
